Sökning: id:"swepub:oai:prod.swepub.kib.ki.se:124026905" >
Sustained inhibitio...
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
-
Tak, PP (författare)
-
Rigby, W (författare)
-
Rubbert-Roth, A (författare)
-
visa fler...
-
Peterfy, C (författare)
-
- van Vollenhoven, RF (författare)
- Karolinska Institutet
-
Stohl, W (författare)
-
Healy, E (författare)
-
Hessey, E (författare)
-
Reynard, M (författare)
-
Shaw, T (författare)
-
visa färre...
-
(creator_code:org_t)
- 2011-10-19
- 2012
- Engelska.
-
Ingår i: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 71:3, s. 351-357
- Relaterad länk:
-
https://ard.bmj.com/...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- In the IMAGEstudy, rituximab plus methotrexate (MTX) inhibited joint damage and improved clinical outcomes at 1 year in MTX-naïve patients with early active rheumatoid arthritis.ObjectiveThe aim of this study was to assess joint damage progression and clinical outcomes over 2 years.MethodsPatients (n=755) were randomised to receive rituximab 2×500 mg+MTX, 2×1000 mg+MTX or placebo+MTX. The placebo-controlled period continued to week 104. Two-year end points were defined as secondary or exploratory and included change in total Genant-modified Sharp score (mTSS), total erosion score and joint space narrowing score from baseline to week 104. Clinical efficacy and physical function end points were also assessed.ResultsAt 2 years, rituximab 2×1000 mg+MTX maintained inhibition of progressive joint damage versus MTX alone (mTSS change 0.41 vs 1.95; p<0.0001 (79% inhibition)), and a higher proportion of patients receiving rituximab 2×1000 mg+MTX had no radiographic progression over 2 years compared with those receiving MTX alone (57% vs 37%; p<0.0001). Contrary to 1-year results, exploratory analysis of rituximab 2×500 mg+MTX at 2 years showed that progressive joint damage was slowed by ∼61% versus placebo+MTX (mTSS, exploratory p=0.0041). Improvements in clinical signs and symptoms and physical function seen after 1 year in rituximab-treated patients versus those receiving placebo were maintained at year 2. Safety profiles were similar between groups.ConclusionsTreatment with rituximab 2×1000 mg+MTX was associated with sustained improvements in radiographic, clinical and functional outcomes over 2 years.Clinical trials.gov identifier NCT00299104.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tak, PP
-
Rigby, W
-
Rubbert-Roth, A
-
Peterfy, C
-
van Vollenhoven, ...
-
Stohl, W
-
visa fler...
-
Healy, E
-
Hessey, E
-
Reynard, M
-
Shaw, T
-
visa färre...
- Artiklar i publikationen
-
Annals of the rh ...
- Av lärosätet
-
Karolinska Institutet